Potential of Ferritin-Based Platforms for Tumor Immunotherapy

• Published in: Molecules (Basel, Switzerland) Vol. 27; no. 9; p. 2716
• Main Authors: Xu, Xiaoling, Tian, Kewei, Lou, Xuefang, Du, Yongzhong
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 22.04.2022; MDPI
• Subjects: Animal models; Antigen presentation; Antioxidants; Clinical trials; Coronaviruses; Dendritic cells; Drug delivery; Drug delivery systems; Drugs; Ferritin; Genetic engineering; Homeostasis; Immunomodulation; Immunomodulators; Immunosuppressive agents; Immunotherapy; Iron; Lymph nodes; Lymphocytes; M2 tumor-associated macrophages; Macrophages; Melanoma; Particle size; Peptides; Physiology; Proteins; Review; Self-assembly; Severe acute respiratory syndrome coronavirus 2; Spleen; Tumor cells; tumor-associated fibroblasts; Tumors; Vaccines; ferritin; M2 tumor-associated macrophages; dendritic cells; tumor cells; tumor-associated fibroblasts; immunotherapy
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules27092716

Ferritin is an iron storage protein that plays a key role in iron homeostasis and cellular antioxidant activity. Ferritin has many advantages as a tumor immunotherapy platform, including a small particle size that allows for penetration into tumor-draining lymph nodes or tumor tissue, a unique structure consisting of 24 self-assembled subunits, cavities that can encapsulate drugs, natural targeting functions, and a modifiable outer surface. In this review, we summarize related research applying ferritin as a tumor immune vaccine or a nanocarrier for immunomodulator drugs based on different targeting mechanisms (including dendritic cells, tumor-associated macrophages, tumor-associated fibroblasts, and tumor cells). In addition, a ferritin-based tumor vaccine expected to protect against a wide range of coronaviruses by targeting multiple variants of SARS-CoV-2 has entered phase I clinical trials, and its efficacy is described in this review. Although ferritin is already on the road to transformation, there are still many difficulties to overcome. Therefore, three barriers (drug loading, modification sites, and animal models) are also discussed in this paper. Notwithstanding, the ferritin-based nanoplatform has great potential for tumor immunotherapy, with greater possibility of clinical transformation.